CX3CL1 and cancer: Furthermore, a significant (p = 0.034) reduction of Fractalkine, also known as CX3CL1 was observed in rAREG treated mouse ascites, which has been found to be a key mediator in of cytotoxic T cell immunity and associated with improved prognosis in numerous cancer subtypes (Conroy and Lysaght, 2020) (Figure 6E).